The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing

No abstract is available for this paper.

• Publication year

  1991

• Venue

  International Journal of Gynecologic Cancer

• Publication date

  1991-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1525-1438.1991.tb00041.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase II Trial of Mitomycin in Patients with Epithelial Ovarian Carcinoma Resistant to Cisplatin or Carboplatin

  1990cited by this paper
• Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.

  1990cited by this paper
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

  1990cited by this paper
• Cisplatin/carboplatin cross-resistance in ovarian cancer.

  1989cited by this paper
• Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

  1987cited by this paper
• RANDOMISED COMPARISON OF CISPLATIN WITH CYCLOPHOSPHAMIDE/CISPLATIN AND WITH CYCLOPHOSPHAMIDE/DOXORUBICIN/ CISPLATIN IN ADVANCED OVARIAN CANCER

  1987cited by this paper
• Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.

  1986cited by this paper
• Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

  1985cited by this paper
• Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

  1984cited by this paper
• Cis‐platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens

  1983cited by this paper

• Pharmaceutical Management of Ovarian Cancer: Current Status

  2019cites this paper
• Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer

  2016cites this paper
• Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.

  2013cites this paper
• Surgical Treatment of Ovarian Cancer

  2013cites this paper
• Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy

  2013cites this paper
• Pharmaceutical Management of Ovarian Cancer

  2012cites this paper
• Pharmacoeconomic Considerations in Treating Ovarian Cancer

  2012cites this paper
• Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

  2011cites this paper
• Evidence-based chemotherapeutic management of potentially platinum-sensitive recurrent ovarian cancer

  2010cites this paper
• Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer.

  2004cites this paper
• Chapter 32 – Decision-Making in the Management of Recurrent Epithelial Ovarian Cancer

  2004cites this paper
• Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

  2004cites this paper
• Second-line chemotherapy of epithelial ovarian cancer

  2003cites this paper
• Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions

  2003cites this paper
• Role of chemotherapy in the management of ovarian cancer

  2002cites this paper
• Chemotherapy for advanced epithelial ovarian carcinoma.

  2002cites this paper
• Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?

  2001cites this paper
• Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?

  2001cites this paper
• Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

  2001cites this paper
• Recent Advancements in the Treatment of Epithelial Ovarian Cancer *

  2001cites this paper
• Second-line treatment of ovarian cancer.

  2000cites this paper
• 15 Jahre gute Lebensqualität mit Ovarialkarzinom FIGO III b, davon 10 Jahre mit ausgedehnter viszeraler Metastasierung - ein exzeptioneller Krankheitsverlauf

  2000cites this paper
• The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life.

  1999cites this paper
• Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.

  1999cites this paper
• Evidence that a “treatment-free interval of less than 6 months” does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma

  1998cites this paper
• Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups.

  1998cites this paper
• Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.

  1998cites this paper
• "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?

  1998cites this paper
• Gemcitabine: a cytidine analogue active against solid tumors.

  1997cites this paper
• Prognostic factors in salvage therapy of ovarian cancer.

  1997cites this paper
• Frontiers of Ovarian Cancer Therapy.

  1996cites this paper
• Section Review Oncologic, Endocrine & Metabolic Treatments, topics, and trends in ovarian cancer

  1995cites this paper
• Treatment of advanced epithelial ovarian cancer: past, present and future.

  1995cites this paper
• Tamoxifen in patients with advanced epithelial ovarian cancer

  1994cites this paper
• Gemcitabine in Ovarian Cancer

  1994cites this paper
• Primary treatment of epithelial ovarian malignancies

  1993cites this paper
• Hexamethylmelamine in platinum-resistant ovarian cancer: how active?

  1992cites this paper
• Prognostic indices in ovarian cancer

  1992cites this paper